Keywords: Ranbaxy, Glaxo, Valtrex, genital herpes
Big upside for Ranbaxy as it launches generic version of Glaxos herpes drug Valtrex
Article | 27 November 2009
Ranbaxy Laboratories, Indias top drugmaker in terms of sales, has just launched a copycat version of Glaxos Valtrex (valacyclovir hydrochloride)an antiviral drug for treating genital herpes, cold sores and shinglesin the US. Valtrex boasts annual sales of $2.2bn in America. Following FDA approval for two dosages of the medicine, it is producing 500mg and 1 gm tablets.
Ranbaxy had been first to file (FTF) an application for a copycat version of Valtrex and was therefore granted 180-day marketing exclusivity for it. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
